GlaxoSmithKline Pharmaceuticals share news, announcements and annual reports
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
GlaxoSmithKline Pharmaceuticals Limited · Formerly Glaxo (India) · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1969 on BSE, Dec 2000 on NSE
Last close ₹2,494.30down ₹20.80 (0.83%)BSE ₹2,483.55
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,515.10.
30 Oct: open ₹2,527.60, high ₹2,528.90, low ₹2,479.30
52-week range of traded prices to 30 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹42,255 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.56
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,34965.0% delivered
GlaxoSmithKline Pharmaceuticals share news and announcements
719 announcements, routine notices left out, newest first. Page 11 of 15.
Apr 2017
Mar 2017
Feb 2017
11 Feb · Results
Jan 2017
Oct 2016
27 Oct · Results
Sep 2016
19 Sep · Legal
The exchange asked on 16 Sep 2016
12 Sep · Analysts
Aug 2016
31 Aug · News Verification
Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited with respect to recent news item captioned "GSK Pharma to sell 60 acre land parcel in Thane, valued at 1400-1800 Cr". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.5 Aug · Analysts
Jul 2016
29 Jul · Regulation 44(3) of SEBI (LODR), Reg., 2015
May 2016
Apr 2016
Feb 2016
Jan 2016
Dec 2015
Oct 2015
31 Oct · Management
Pursuant to Clause 30 of the Listing Agreement :1. Mr. P V Nayak, Non-Executive & Independent Director has ceased to be a Director of the Company from close of the business hours on 31st October 2015.2. Mr. V Thyagarajan, Non-Executive Director has ceased to be a Director of the Company from close of the business hours on 31st October 2015.
Sep 2015
Aug 2015
1 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2015
Jun 2015
8 Jun · Legal
Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited with respect to recent news item captioned "CCI slaps Rs. 64cr fine on GlaxoSmithKline, Sanofi". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
May 2015
25 May · Code of Conduct under SEBI(PIT) Reg., 2015
18 May · Meeting
Annual General Meeting of the Company held on July 31, 2015.